Loxo Oncology Inc Logo Image

Loxo Oncology Inc

Loxo Oncology Inc has reached its limit for report views.

Please check back to see if Loxo Oncology Inc has upgraded their profile page to allow their financial information to be viewed. In the meantime, here are a few annual reports from similar companies.

Most Recent Annual Report

2015 Form 10K

Loxo Oncology Inc

Loxo Oncology Inc does not currently have any hardcopy reports available on AnnualReports.com. Click the button below to be notified when hardcopies become available.



About Loxo Oncology Inc

11-50 Employees
Based in Stamford, Connecticut

Loxo Oncology, Inc. engages in the discovery, development, and commercialization of cancer therapies in the United States. Its lead product candidate includes LOXO-101, an oral and selective inhibitor of tropomyosin receptor kinase (TRK), which is in a Phase I dose escalation trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.

Ticker:
LOXO
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol